Psychedelics biotech Silo Pharma Inc. (NASDAQ:SILO) and Columbia University are developing a novel compound formulation as a prophylactic treatment for stress, anxiety and PTSD.
Ketamine-based SPC-15 is currently undergoing studies on dosage and delivery methods. These, coupled with published preclinical data, altogether show promising results for treating cognitive impairment, PTSD, and other stress-related disorders.
See Also: Can Marijuana Treat Autism, OCD & Irritable Bowel Syndrome?
The SPC-15 treatment protocol “predicts levels of severity or progression of stress-related disorders and their metabolomic biomarkers’ response to pharmacological treatments,” Silo Pharma CEO Eric Weisblum explained.
The company holds a recently granted U.S. patent covering SPC-15 as a method for the treatment and prevention of stress-induced affective disorders in females.
Bright Minds Gets International Go-Ahead
Meanwhile, Bright Minds Biosciences Inc. (NASDAQ:DRUG) had its patent application covering phenethylamine (aka PEA)-class compounds reviewed and approved by the International Searching Authority. This indicates the company’s lead compounds as novel and inventive in a non-binding “written opinion” letter.
See Also: Mood Disorders Could Get An Alternative Treatment With This Next-Gen, Non-Hallucinogenic Psychedelic
These compounds targeting the 5-HT2A and 5-HT2A/5-HT2C receptors are potentially best-in-class, with an optimized short half-life, high potency, and extreme selectivity, the company claims.
One of the compounds is BMB-202 — the company’s lead 5-HT2A agonist. It has shown a superior potency compared to psilocin in vitro. Moreover, while it has not shown significant activity at other 5-HT receptors, it is fast-acting, holds a short duration (around two hours), and has demonstrated antidepressant properties in vivo.
Photo: Benzinga edit with photo by Raimundo79 and Sergey Nivens on Shutterstock.
Benzinga’s PCC 2023
Missed our Psychedelics Capital Conference? Here’s some EXCLUSIVE coverage from the event’s second edition:
-
Investing In The Unique Growth Market Of Psychedelics
-
EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps
-
Infrastructure Built For Healing: ‘Consolidation And Legitimacy Are Crucial For Psychedelic Industry Growth’
-
Ketamine Therapy Leaders Share Bold Vision For Future At Benzinga’s Psychedelics Capital Conference
-
In Reinventing Mental Health & Next-Gen Psychedelics, ‘Access And Clinical Data Are Key’
-
Making The World A Better Place, How Psychedelics Are Helping
